Virtus ETF Advisers LLC Takes Position in Clovis Oncology (NASDAQ:CLVS)

Virtus ETF Advisers LLC purchased a new stake in Clovis Oncology (NASDAQ:CLVS) during the 2nd quarter, Holdings Channel reports. The firm purchased 62,509 shares of the biopharmaceutical company’s stock, valued at approximately $930,000.

Several other hedge funds have also added to or reduced their stakes in CLVS. Westfield Capital Management Co. LP acquired a new stake in Clovis Oncology during the first quarter worth approximately $20,016,000. Redmile Group LLC boosted its position in Clovis Oncology by 12.4% during the first quarter. Redmile Group LLC now owns 4,563,929 shares of the biopharmaceutical company’s stock worth $113,277,000 after acquiring an additional 503,400 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Clovis Oncology by 41.8% during the second quarter. Candriam Luxembourg S.C.A. now owns 1,108,123 shares of the biopharmaceutical company’s stock worth $16,405,000 after acquiring an additional 326,500 shares during the last quarter. Spark Investment Management LLC boosted its position in Clovis Oncology by 51.2% during the first quarter. Spark Investment Management LLC now owns 673,100 shares of the biopharmaceutical company’s stock worth $16,706,000 after acquiring an additional 227,800 shares during the last quarter. Finally, Gamco Investors INC. ET AL boosted its position in Clovis Oncology by 264.8% during the second quarter. Gamco Investors INC. ET AL now owns 199,550 shares of the biopharmaceutical company’s stock worth $2,967,000 after acquiring an additional 144,850 shares during the last quarter. Institutional investors and hedge funds own 91.69% of the company’s stock.

In other Clovis Oncology news, Director Thorlef Spickschen bought 9,200 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $5.46 per share, with a total value of $50,232.00. Following the purchase, the director now owns 49,576 shares in the company, valued at approximately $270,684.96. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director James C. Blair bought 40,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $5.84 per share, for a total transaction of $233,600.00. Following the purchase, the director now owns 33,439 shares in the company, valued at approximately $195,283.76. The disclosure for this purchase can be found here. In the last three months, insiders bought 107,800 shares of company stock worth $612,094 and sold 2,597 shares worth $30,139. Company insiders own 8.30% of the company’s stock.

NASDAQ CLVS traded down $0.13 during mid-day trading on Friday, hitting $5.58. The company’s stock had a trading volume of 118,292 shares, compared to its average volume of 3,114,332. The firm has a market capitalization of $315.39 million, a P/E ratio of -0.80 and a beta of 1.91. The company has a debt-to-equity ratio of 8.04, a current ratio of 3.57 and a quick ratio of 3.32. Clovis Oncology has a 52-week low of $4.98 and a 52-week high of $34.63. The stock’s fifty day simple moving average is $6.97 and its two-hundred day simple moving average is $16.33.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($0.57). Clovis Oncology had a negative return on equity of 372.68% and a negative net margin of 332.18%. The business had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $34.92 million. During the same quarter in the prior year, the firm earned ($1.94) earnings per share. Clovis Oncology’s quarterly revenue was up 38.8% compared to the same quarter last year. On average, equities analysts forecast that Clovis Oncology will post -7.51 earnings per share for the current fiscal year.

A number of analysts recently issued reports on CLVS shares. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 27th. JPMorgan Chase & Co. restated a “hold” rating and set a $27.00 target price on shares of Clovis Oncology in a research report on Monday, June 3rd. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Gabelli reissued a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 2nd. Finally, G.Research reissued a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $25.09.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: What is the accumulation/distribution indicator?

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.